UniRDC™ is a proprietary discovery platform, which rationalizes and accelerates the discovery process of RDC drug candidates. UniRDC™ enables a short discovery timeline of 18 months or less from a target to an RDC development candidate with human biodistribution data, which has been repeatedly validated internally. 

UniRDC™ covers a range of modalities including small molecule, cyclic peptide, and nanobody. It is centered on a rich set of proprietary synthetic chemistry and protein engineering tool kits including Clear-X™ linker technology and Res-X™ modification methods. Such tool kits have been proven to be essential to rapidly turn an affinity matured binder to a development candidate with therapeutically optimal biodistribution profile.